alpha lipoic acid supplements
Lipoic acid is an organosulfur compound, one enantiomer of which is an essential cofactor for many enzyme complexes. This yellow solid is a carboxylic acid and features a cyclic disulfide, or ditholane ring, functional group. The R-enantiomer is biosynthesized and used as a cofactor. It is essential for aerobic life and is a common and sometimes controversial dietary supplement. It is usually called "lipoic acid," but this is not the form it takes in life. dihydrolipoic acid is the reduced form which is mostly how the sulfurs exist intracellularly. "Lipoate" is the conjugate base of lipoic acid, and this is the form carboxylic acids take at physiological conditions. So free lipoic acid inside the cell could correctly be called dihydrolipoate. Most intracellular lipoic acid is not free, because it is made and attached to the enzyme complexes that use it. As a cofactor it is covalently bound via an amide bond to a specific lysine residue of lipoyl domains. One of the most visible roles of lipoic acid is as a cofactor in aerobic metabolism, specifically the pyruvate dehydrogenase complex. Lipoate participates in transfer of acyl or methylamine groups in 2-oxoacid dehydrogenases (2-OADH) and glycine cleavage complexes (GCV), respectively.
History
Lipoate was first called pyruvate oxidation factor (POF) by Irwin C. Gunsalus, the former chair of Biochemistry at the University of Illinois at Urbana-Champaign. This was after the observation by many groups that POF functioned as an essential growth factor for Enterococci, which lack the ability to make lipoate. The structure was determined in a collaboration of Gunsalus with Lester Reed and Eli Lilly; the synthetic compound designated α-lipoic acid proved to be the correct molecule. The configuration found in vivo was later found to be the R-enantiomer.
The first human clinical studies using alpha-lipoic acid (ALA) in the United States were conducted by Fredrick C. Bartter, Burton M. Berkson, and associates from the National Institutes of Health in the 1970’s. They administered intravenous ALA to 79 people with acute and severe liver damage at various medical centers across the United States and 75 recovered full liver function. Drs. Bartter and Berkson were appointed by the FDA as principal investigators for this therapeutic agent as an investigational drug and Dr. Berkson went on to use it successfully for the treatment of chronic liver disease (viral hepatitis, autoimmune hepatitis, etc).
Biosynthesis and attachment
The precursor to lipoic acid, octanoic acid, is made via fatty acid biosynthesis. In eukaryotes a second fatty acid biosynthetic pathway in the mitochondria is used for this purpose. The octanoate is transferred from a thioester of acyl carrier protein to a amide of the lipoyl domain by an octanoyltransferase. The sulfur centers are inserted into the 6th and 8th carbons of octanoate via the a radical s-adenosyl methionine mechanism, by lipoyl synthase. The sulfurs are from the lipoyl synthase polypeptide. As a result, lipoic acid is synthesized on the lipoyl domain and no free lipoic acid is produced. Lipoic acid can be removed whenever proteins are degraded and by the action of a specific enzyme, called lipoamidase. Free lipoic can be attached to the lipoyl domain by the enzyme lipoate protein ligase. Like all ligases, this enzyme requires ATP. Lipoate protein ligases proceed via a enzyme bound lipoyl adenylate intermediate.
Lipoic acid-dependent complexes
2-OADH transfer reactions occur by a similar mechanism in the PDH complex, 2-oxoglutarate dehydrogenase (OGDH) complex, branched chain oxoacid dehydrogenase (BCDH) complex, and acetoin dehydrogenase (ADH) complex. The most studied of these is the PDH complex. These complexes have three central subunits: E1-3, which are the decarboxylase, lipoyl transferase, and dihydrolipoamide dehydrogenase respectively. These complexes have a central E2 core and the other subunits surround this core to form the complex. In the gap between these two subunits, the lipoyl domain ferries intermediates between the active sites. The geometry of the PDH E2 core is cubic in Gram-negative bacteria or dodecahedral in Eukaryotes and Gram-positive bacteria. Interestingly the 2-OGDH and BCDH geometry is always cubic. The lipoyl domain itself is attached by a flexible linker to the E2 core and the number of lipoyl domains varies from one to three for a given organism. The number of domains has been experimentally varied and seems to have little effect on growth until over nine are added, although more than three decreased activity of the complex. The lipoyl domains within a given complex are homogenous, while at least two major clusters of lipoyl domains exist in sequenced organisms.
The glycine cleavage system differs from the other complexes, and has a different nomenclature. In this complex the H protein is a free lipoyl domain with additional helices, the L protein is a dihydrolipoamide dehydrogenase, the P protein is the decarboxylase, and the T protein transfers the methylamine from lipoate to tetrahydrofolate (THF) yielding methylene-THF and ammonia. Methylene-THF is then used by serine hydroxymethyltransferase (SHMT) to synthesize serine from glycine. This system is used by many organisms and plays a crucial role in the photosynthetic carbon cycle.
Biological sources
Lipoic acid is found in almost all foods, but slightly more so in kidney, heart, liver, spinach, broccoli, and yeast extract. Naturally occurring lipoic acid is always covalently bound and not immediately available from dietary sources. Additionally, the amount of lipoic acid present is very low. For example: the purification of lipoic acid to determine its structure used an estimated 10 tons of liver residue, which yielded 30 mg of lipoic acid. As a result, all lipoic acid available as a supplement is chemically synthesized.
Use as a dietary supplement
Since the early 1990s lipoic acid has been consumed as a dietary supplement, typical doses are 100–200 mg/day. A chronic/carcinogenicity study in rats reported that racemic lipoic acid was found to be non-carcinogenic and did not show any evidence of target organ toxicity. The NOAEL is considered to be 60 mg/kg bw/day.
Antioxidant
Lipoic acid was first postulated to be an effective antioxidant when it was found it prevented the symptoms of vitamin C and vitamin E deficiency. Dihydrolipoic acid is able to regenerate (reduce) antioxidants, such as glutathione, vitamin C and vitamin E. . It is able to scavenge reactive species in vitro, though there is little or no evidence that this actually occurs in vivo. The relatively good scavenging activity of lipoic acid is due to the strained conformation of the 5-membered ring in the intramolecular disulfide. In cells, lipoic acid can theoretically be reduced to dihydrolipoic acid (ΔE= -0.288), though significant quantities of dihydrolipoic acid derived from orally-ingested lipoic acid have never been demonstrated. Recent findings suggest that lipoic acid's curative effects are due to modulation of regulation in eukaryotes . This likely occurs due to lipoic acid acting as an oxidant, not a reductant.
Disease Treatment
Lipoic acid has been shown in cell culture experiments to increase cellular uptake of glucose by recruiting the glucose transporter GLUT4 to the cell membrane, suggesting its use in diabetes, although these findings are controversial as lipoic acid worsened the condition of type 1 diabetes induced rats. Studies of rat aging have suggested that the use of Acetyl-L-carnitine and lipoic acid results in improved memory performance and delayed structural mitochondrial decay. As a result, it may be helpful for people with Alzheimer's disease or Parkinson's disease. In 2009 a study found that it reduced triglycerides in mice.
ALA has been used for the treatment of various cancers for which no effective treatments exist .
Use as a chelator
Owing to the presence of two thiol groups, dihydrolipoic acid is a chelating agent. Lipoic acid administration can significantly enhance biliary excretion of inorganic mercury in rat experiments, although it is not known if this is due to chelation by lipoic acid or some other mechanism. Lipoic acid has the potential to cross the blood-brain barrier in humans unlike DMSA and DMPS, however its effectiveness is heavily dependent on the dosage and frequency of application. Lipoic acid is not approved by the U.S. Food and Drug Administration as a chelating agent.
R-enantiomer and S-enantiomer
Normally, only the R-enantiomer of lipoic acid occurs naturally, but the S-enantiomer can assist in the reduction of the R-enantiomer when a racemic (50% R-enantiomer and 50% S-enantiomer) mixture is given. However, some studies have suggested that the S-enantiomer in fact has an inhibiting effect on the R-enantiomer, reducing its biological activity. Furthermore, while a racemic mixture of lipoic acid has been found to increase the expression of GLUT4, responsible for glucose uptake in cells, the R-enantiomer of lipoic acid has been shown to do so by a greater amount than either the S-enantiomer or the racemic mixture. However, as stated by the Linus Pauling Institute, "virtually all of the published studies of LA supplementation in humans have used racemic LA".
References
- ^ Teichert J, Hermann R, Ruus P, Preiss R (November 2003). "Plasma kinetics, metabolism, and urinary excretion of alpha-lipoic acid following oral administration in he
Latest News
Slumdog child actor moves into new home from slum
One of the child actors from the hit movie Slumdog Millionaire, plucked from his life of obscurity in an Indian slum, has moved with his family to a new home.